

**Capillary angiopathy and aquaporin-4 after A $\beta$  immunisation in Alzheimer's disease – potential relevance to Amyloid-Related Imaging Abnormalities**

Charlotte H. Harrison<sup>1</sup>, Kenji Sakai<sup>1,2</sup>, David A. Johnston<sup>3</sup>, Clive Holmes<sup>1,4</sup>, Delphine Boche<sup>1\*</sup>, James AR Nicoll<sup>1,5</sup>

<sup>1</sup>Clinical Neurosciences, Clinical and Experimental Science, Faculty of Medicine, University of Southampton, Southampton, UK

<sup>2</sup>Department of Neurology, Kanazawa University Hospital, Kanazawa, Japan

<sup>3</sup>Biomedical Imaging Unit, Faculty of Medicine, University of Southampton, Southampton, UK

<sup>4</sup>Memory Assessment and Research Centre, Moorgreen Hospital, Southern Health Foundation Trust, Southampton, UK

<sup>5</sup>Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

**\*Corresponding author**

Prof Delphine Boche, email: [d.boche@soton.ac.uk](mailto:d.boche@soton.ac.uk)

**Keywords:** Alzheimer's disease, amyloid angiopathy, capillaries, vascular biology, human brain, aquaporin, A $\beta$  immunisation.

**Running title:** Capillary CAA and aquaporin 4 after A $\beta$  immunotherapy

## **Abstract**

*Aims:* Amyloid-related imaging abnormalities (ARIA) have hampered clinical trials and therapeutic use of amyloid- $\beta$  (A $\beta$ ) immunotherapy for Alzheimer's disease (AD), with the cause of the white matter oedema (ARIA-E) unknown. Aquaporin 4 (AQP4), present in astrocyte endfeet, controls water flow across the blood-brain barrier. Experimental studies suggest that as A $\beta$  plaques are cleared following immunotherapy, capillary angiopathy (capCAA) increases, displacing astrocyte endfeet allowing influx of extracellular water (oedema). We sought neuropathological evidence for this mechanism in immunised AD patients.

*Methods:* Brains of 16 Alzheimer's patients immunised against A $\beta$ 42 (iAD, AN1792, Elan Pharmaceuticals) and 28 unimmunized Alzheimer's (cAD) cases were immunolabelled and quantified for A $\beta$ 42 and AQP4.

*Results:* CapCAA was 3.5 times higher in iAD ( $p=0.009$ ). No difference between the groups was identified in the proportion of capillaries wrapped by AQP4 or AQP4 protein load. However, capCAA in iAD negatively correlated with AQP4 load ( $r = -0.498$ ,  $p<0.001$ ), suggesting disturbance of AQP4 in presence of capCAA.

*Conclusions:* After A $\beta$  immunotherapy, capCAA was increased, likely reflecting the drainage of soluble A $\beta$  towards the vasculature and providing a potential mechanism to disrupt AQP4-containing astrocyte endfeet, resulting in ARIA-E. We did not identify alterations in AQP4, potentially because of limitations in the timing of the post-mortem analysis. Given the recent licencing of A $\beta$  immunotherapy, the field must prioritise obtaining neuropathological correlates of ARIA to explore its mechanisms further.

## Introduction

The amyloid cascade hypothesis [1] stipulates that amyloid- $\beta$  (A $\beta$ ) aggregation is the initiating event in AD. The hypothesis has been tested therapeutically in a range of active and passive immunotherapy trials targeted against A $\beta$  [2]. The first clinical trial, using an active anti-A $\beta$ 42 vaccine (Elan Pharmaceuticals AN1792) [3] failed to demonstrate slowing of cognitive decline [4], while *post-mortem* findings showed clearance of plaques [4-7] and exacerbation of cerebral amyloid angiopathy (CAA) [8, 9]. This was attributed to plaques being disaggregated by anti-A $\beta$  antibodies [10] and phagocytic microglia [11], permitting A $\beta$  to enter the perivascular drainage pathway [12-14] and be removed from the brain [8, 15].

Subsequent A $\beta$  immunotherapy trials incorporated systematic brain imaging into their study design [16], allowing the identification of amyloid-related imaging abnormalities (ARIA) as radiological observations interpreted as representing microhaemorrhages (ARIA-H) and oedema (ARIA-E) [16-18]. ARIA has become a persistent obstacle in A $\beta$  immunotherapy trials [2, 19], its presence limiting dosing regimens and curtailing clinical trials, hampering completion of studies to assess efficacy. ARIA is associated with possession of the apolipoprotein  $\epsilon$ 4 allele (APOE4), higher antibody doses and localised reduction of amyloid assessed *in vivo* by PiB PET scans [17, 20]. ARIA-H has been proposed to be due to increased severity of CAA following immunotherapy causing microbleeds [8, 15]. ARIA-E is defined as radiological hyperintensity in the grey or white matter or leptomeninges of the brain, which represent oedema [16], in particular seems to be restricted to the weeks after onset of treatment and is reversible. From a pathophysiological point of view, vascular permeability [8, 16], inflammation [15, 21, 22] and APOE isoform [16] have been proposed to play a role in causing ARIA-E; however the exact mechanism remains unknown.

Of the two main pathogenic isoforms of A $\beta$ , A $\beta$ 42 is the main constituent of parenchymal plaques and capillary cerebral amyloid angiopathy (capCAA) located within the capillary basement membrane [23, 24]; whereas A $\beta$ 40 predominates in the walls of arteries and arterioles, forming CAA [24]. CAA is classified into two distinct histopathological phenotypes, with the presence of capCAA and the possession of an APOE4 allele distinguishing type 1 CAA from type 2 [25, 26]. Unlike arterial and arteriolar CAA, capCAA may be surrounded by tau deposits and reactive microglia [27] and results in functional blood flow disturbances, which may exacerbate A $\beta$ -mediated neurotoxicity [28]. Therefore, although capCAA is typically an infrequent feature of AD [29, 30], it may be biologically important in its pathogenesis. In PDAPP mice, capCAA was increased after passive A $\beta$  immunisation [31], and although capCAA has been noted to occur in human AD following A $\beta$  immunotherapy, it has not been systematically studied or quantified [6, 9].

Aquaporin-4 (AQP4), the principal water transporter in the CNS [32, 33], offers a potential link between the vascular A $\beta$  changes following immunisation and ARIA-E. AQP4 is

expressed by astrocytes [34] at interfaces between brain parenchyma and fluid, most notably in perivascular astrocyte endfeet [35-37], and is integral to maintain astrocyte function, including fluid and ion homeostasis [33, 38, 39]. Experimental [31, 40-42] and human studies [40] have demonstrated a relationship between A $\beta$  deposits and AQP4 distribution. In areas of vascular A $\beta$ , AQP4 is redistributed away from perivascular endfeet, with a concurrent clustering of AQP4 around parenchymal plaques [43-46]. In the PDAPP mouse model immunised against A $\beta$ , AQP4 was reduced in areas of newly formed capCAA. In addition, there was structural disorganisation of astrocyte endfeet [31], displacing endfeet away from their normally tight contact with endothelial cells, potentially allowing efflux of water from the blood into the brain parenchyma, causing extracellular water accumulation. Images suggested a similar mechanism may occur in human AD [31]. However, no such study has been performed to date in the brains of AD patients immunised against A $\beta$  and this might provide important insights into the pathophysiology of ARIA-E. We therefore hypothesise that an increase in capCAA may occur following A $\beta$  immunisation and cause displacement of astrocyte AQP4-containing endfeet away from the vessel wall, or relocation of AQP4 within astrocytes away from the endfeet, leading to impaired water transfer across the capillary and resulting in interstitial oedema (ARIA-E).

In this study, we took the opportunity offered by our unique neuropathological cohort of immunised AD cases to explore certain components of the aforementioned hypothesis. Specifically, by assessing whether A $\beta$  removal was associated with (i) increased capCAA (ii) decreased AQP4 expression and (iii) displacement of AQP4-containing astrocyte endfeet away from capillaries.

## **Materials and Methods**

### *Characteristics of the cases*

Clinical and neuropathological follow-up of Alzheimer's patients (age range 63-89 years) enrolled in the Elan Pharmaceuticals phase 1 trial of AN1792 was previously reported [3, 4, 7]. Patients (or carers) were invited to consent to *post-mortem* neuropathological examination, and subsequently, tissue was available from 22 immunised patients with 16 having a neuropathological diagnosis of AD (termed iAD) (Table 1). Six had another cause of dementia and were excluded from further analysis. One patient (case no. 1) required imaging in life, which demonstrated features of meningoencephalitis and neuroradiological features consistent with the later defined ARIA-E [5, 16]. The case IDs were not known to anyone outside the research group.

As there were inadequate numbers of *post-mortem* placebo treated samples from the original trial, 28 unimmunised AD cases used as controls (cAD; age range 63-88 years) were

sourced from the South West Dementia Brain Bank. Cases were matched as closely as possible for age at death, APOE genotype and sex.

### *Immunohistochemistry*

Four  $\mu\text{m}$ -thick sections of formalin fixed paraffin-embedded tissue were immunostained for A $\beta$ 42 (clone 21F12, 1:4000, Prothena Biosciences). Sections from three neocortical areas – the medial frontal lobe, middle temporal lobe and inferior parietal lobule – were immunostained for AQP4 (H-80, Santa Cruz, Dallas, USA, 1:1000) and A $\beta$ 42 (Clone 21F12, Elan Pharmaceuticals). Immunolabelling was performed using the appropriate antigen retrieval method, and the signal was amplified via the avidin-biotin-peroxidase complex method (Vectastain Elite) for a detection with 3,3'-diaminobenzidine as the chromogen (Vector Laboratories, Peterborough, UK). All experiments included a negative control slide incubated in buffer with no primary antibody, and a positive control slide.

### *Quantification*

Slides stained for A $\beta$ 42 and AQP4 were scanned using Olympus VS110 slide scanner at magnification x40 (CapCAA, AQP4 endfeet) or x20 (A $\beta$ 42 and AQP4 loads). Olympus VS-Desktop software (v2.9) was used to extract regions of interest (ROIs) with the quantification performed in each neocortical region and blind to immunisation status.

*CapCAA:* Thirty-five ROIs of  $1.58\text{mm}^2$  each were placed contiguously in the area of cerebral cortex sampled in adjacent slides for A $\beta$ 42 and AQP4. Identification of a capillary required an identifiable endothelial nucleus and/or cuboidal erythrocytes in the lumen, and a diameter less than  $10\mu\text{m}$ . The number of capCAA vessels was counted in each ROI.

*AQP4 capillary endfeet:* The number of capillaries surrounded by AQP4-positive endfeet (identified by the presence of AQP4 staining surrounding the capillary outer wall) were counted in 15 ROIs placed contiguously.

*A $\beta$ 42 and AQP4 loads:* Images of thirty ROIs were captured in a zigzag manner to sample the whole thickness of the neocortex. The percentage area of A $\beta$ 42 or AQP4 staining was measured using Image J 1.45v software and expressed as protein load (%) as previously reported [9].

### *Statistical analysis*

Statistical analysis was performed in SPSS (ISM v25) and graphs were generated using GraphPad (PRISM v8). Due to the highly patchy nature of plaque removal observed in the immunised cohort, data from the three neocortical areas were analysed and plotted individually for each parameter used. Normality of the data was assessed using one-sample

Kolmogorov-Smirnoff tests and through examination Q-Q plots. Due to the non-parametric distribution of the data, Mann-Whitney U-test was performed for group comparison. For correlations Pearson's or Spearman's rank test, based on the data distribution, was done within each group to determine the relationships between capCAA, AQP4 and A $\beta$ 42, and in relation with the duration of dementia, age at death, and for the iAD group with the immune response (antibody peak and mean) and the survival time after immunotherapy. Statistical tests were conducted at the 5% for intergroup comparisons and 1% significance level for correlations.

## Results

### *CapCAA*

CapCAA was defined as A $\beta$ 42 located within or in close association with the capillary wall. Examples of an unaffected capillary and capCAA in longitudinal and transverse section are illustrated in Figure 1A-C. CapCAA can be an early consequence of A $\beta$  immunotherapy as it was prominent in association with disrupted plaques in one patient as little as 4 months after the first immunisation dose (Figure 1D). In addition, capCAA in areas of cerebral cortex devoid of plaques was notable in several long-term survivors, up to 14 years after immunisation, indicating it to be a longstanding and/or late recurrent feature (Figure 1E-G).

Quantification of capCAA showed significantly more capCAA in the iAD vs cAD cases (median iAD=3.5 vs cAD=1,  $p=0.009$ ; Figure 1H). In order to determine the influence of *APOE*  $\epsilon$ 4 on capCAA, subgroup analysis was performed according to *APOE*  $\epsilon$ 4 allele status ( $\epsilon$ 4 carriers vs non-carriers). In iAD, there was eight times more capCAA in  $\epsilon$ 4 carriers compared to non-  $\epsilon$ 4 carriers, but with borderline significance (median  $\epsilon$ 4+=4 vs  $\epsilon$ 4-=0.5,  $p=0.056$ ; Figure 1I). In cAD, there was no difference in capCAA based on  $\epsilon$ 4 status ( $p=0.238$ ; Figure 1J).

### *AQP4*

AQP4 expression was detected in the cell bodies and processes of astrocytes (Figure 2A). A patchy staining pattern of AQP4 was noted in the cerebral cortex, likely reflecting astrocytes associated with A $\beta$  plaques, as previously described. There was dense AQP4 immunolabelling in astrocytes located in the subpial cortex and in the periventricular subependymal region. Variable AQP4 expression was observed around large CAA-affected blood vessels with more intense staining attributed to AQP4-positive astrocyte endfeet around some, but not all, capillaries (Figure 2B, 2C).

Quantification of peri-capillary AQP4-positive endfeet showed no significant difference between groups (median iAD=46 vs cAD=56,  $p=0.311$ , Figure 2D). Likewise, quantification of overall cortical AQP4 load showed no significant difference between the groups (median iAD=4.87% vs cAD=8.82%,  $p=0.294$ , Figure 2E). In the subgroup analysis in relation to *APOE* status, there was no difference in AQP4 load or AQP4 endfeet according to  $\epsilon 4$  carrier status between the iAD and cAD groups (data not shown).

#### *The case with known ARIA-E (case no. 1)*

Once the study was unblinded, detailed data were assessed for case no. 1, the only patient in the cohort who had imaging during life, in retrospect defined as having had ARIA-E [5, 7]. As previously reported, the case has extensive removal of A $\beta$  and severe cortical and parenchymal CAA [5]. In this case (black triangle), quantification of capCAA, AQP4 endfeet and AQP4 load fell within the ranges for the other iAD cases (white triangles), not appearing strikingly different in this regard (figures 1H, 2D-E).

#### *Correlations*

Correlations were assessed between capCAA, AQP4 endfeet data, AQP4 and A $\beta$ 42 loads and available clinical information.

In the iAD group, a significant negative correlation was observed between capCAA and AQP4 load ( $r = -0.498$ ,  $p<0.001$ ), and a trend towards an association between AQP4 load and capillary AQP4+ endfeet ( $r = 0.317$ ,  $p=0.032$ ) (Table 2A).

In the cAD cohort, a positive correlation was detected between the AQP4 load and AQP4+ endfeet ( $r = 0.547$ ,  $p<0.001$ ) and a negative correlation between AQP4+ endfeet and age at death ( $r = -0.487$ ,  $p=0.010$ ) (Table 2B). No other associations were observed in either group.

#### **Discussion**

ARIA-E has been a persistent hurdle in clinical trials of A $\beta$  immunotherapy for AD [19]. The presence of MRI signal changes, interpreted as reflecting oedema [16], have occurred in most clinical trials to date, causing significant dose reduction, interruption or trial cessation. Consequently, it is important to understand the pathophysiological basis for this problem, but understanding has been hampered by the paucity of neuropathological analyses of brain tissue from affected patients. There have been few autopsy studies of patients with AD in A $\beta$  immunotherapy trials, other than the cases described here, and none with numbers of cases as large as the cohort investigated in this study. The impact of AN1792 immunotherapy on other aspects of AD pathology has been previously reported [5-9] - notably, the reduction in plaque load [5, 6, 47] and the increase in cerebral amyloid



angiopathy (CAA) [5-8]. This has been attributed to A $\beta$  from plaques being solubilised and drained towards the perivascular pathway (intramural periarterial drainage, IPAD) [13-15] as A $\beta$  is cleared from the brain.

A similar increase in CAA severity has also been identified in animal models of AD immunised against A $\beta$  including accumulation specifically in association with capillaries (capCAA). In AD mouse models, AQP4 the principal water transporter in the brain [32, 33, 48], is displaced away from capillaries following A $\beta$  immunisation [31] – offering potential insight into the pathophysiology of ARIA-E. In this human study, we therefore investigated the impact of immunisation on capCAA and on the distribution of AQP4-positive astrocyte endfeet around capillaries.

### *CapCAA*

Prior to this study, the impact of immunisation on capillaries was unclear. As the capillary basement membrane is at the origin of the perivascular drainage pathway [12], it might be predicted that there would be increased capCAA following immunisation. In this study, we show that capCAA was 3.5 times higher in the immunised AD cohort, consistent with the hypothesis that A $\beta$  from plaques is partly cleared via the perivascular drainage pathway and deposits in the capillary basement membrane forming capCAA [6, 8]. Interestingly, we did not see an association between capCAA and A $\beta$ 42 load in either of the groups. In AD, this might be explained by the very uncommon occurrence of capCAA (median of 1 event in 35 ROIs in AD) relative to the amount of A $\beta$  in the form of plaques. Following immunotherapy, this might imply that only a small proportion of A $\beta$  draining from plaques participates, resulting in the increased capCAA.

APOE4 is the largest genetic risk factor for sporadic AD [49, 50], with E4 homozygotes having a 90% lifetime risk of AD [51, 52]. The presence of ARIA-E has been strongly associated with possession of APOE4 – with each allele conveying 2.55x risk [16]. The risk of the APOE4 allele is thought to relate to the efficiency of APOE-mediated A $\beta$  clearance [52], which may underpin the concurrent increase in capCAA. When we analysed the presence of capCAA according to APOE4 allele status in our cohorts, the E4 carriers in the immunised group had 8 times more capCAA than the non-E4 carriers; whereas no difference was observed in the unimmunised AD group when divided according APOE4 status. Consistent with our observation, two types of CAA have been defined, with type 1 including capCAA and associated with 4 times increased of the APOE4 allele frequency; while type 2 lacks capCAA and is mainly associated with APOE2 [25]. This implies that capCAA is more prone to form in E4 carriers, and CAA-Type 1 might be a contributory event underlying ARIA.

In addition, considering the fundamental role that capillaries play in maintaining cerebral homeostasis, for example in delivering oxygen and glucose and removing CO<sub>2</sub>, it is likely



that disruption of the capillary structure by A $\beta$  deposition will have deleterious consequences. CapCAA has been shown to cause capillary occlusion and functional blood flow disturbances [28], with other neuropathological features of AD such as tau deposits and neuroinflammation observed surrounding capCAA but not CAA [27]. Therefore, exacerbation of capCAA could potentially counteract a possible therapeutic benefit of lowered plaque burden after immunisation [4].

#### *AQP4*

CapCAA may impact surrounding molecular and cellular structures, specifically perivascular astrocyte endfeet and associated AQP4 distribution. Indeed, displacement of AQP4 away from vascular A $\beta$  with a concurrent increase of AQP4 around plaques has been reported previously in experimental models of AD [31, 40-42]. One study in human AD observed AQP4 staining associated with blood vessels in AD with mild CAA; while AD with moderate CAA had a diffuse pattern of AQP4, which was absent in AD with severe CAA [40]. In that study the staining was performed in n=3 per group and not quantified. In our larger and quantitative study, we did not observe changes in AQP4 load *per se* or in the number of capillaries surrounded by AQP4 after A $\beta$  immunisation. However, a significant negative association was found between capCAA and AQP4 load, consistent with the idea that increased capCAA has led to alterations in AQP4 as demonstrated in mice [31].

#### *Implications for ARIA*

A lymphocytic inflammatory reaction to the increased burden of A $\beta$  in the vasculature, has also been proposed to play an important role in generating ARIA [15]. Close parallels have been noted between this post-immunotherapy iatrogenic change and the naturally occurring disorder of CAA-related inflammation [53, 54] in which patients produce anti-A $\beta$  antibodies as an autoimmune response [55, 56]. Both CAA-related inflammation and severe CAA by itself are known to cause alterations on imaging of the underlying cerebral white matter, although the mechanism for this is unclear [57]. Both our own single case known to have ARIA and one other such published case [58] had a lymphocytic reaction in relation to the CAA and so inflammatory processes may have additional or greater relevance to ARIA than capCAA-associated alterations in AQP4.

A crucial limitation affecting all ARIA studies, ours notwithstanding, is the lack of neuropathological correlates. During the clinical phase of the AN1792 phase 1 trial, imaging was not routine and ARIA had not been described. In our cohort, one case retrospectively had imaging features consistent with ARIA-E (case no. 1) [5, 7], occurring nearly a year prior to death. As ARIA-E is a transient phenomenon, occurring 4 – 8 weeks after the first dose and lasting up to 113 days [20, 59], these changes may have fully resolved before death.

This may explain why case no. 1 did not differ obviously from the other immunised AD cases in terms of capCAA, AQP4+ endfeet and AQP4 load. In addition, there may have been ARIA-E occurring in other cases in our cohort, that was not detected clinically or radiologically. Hence, it is challenging to be sure that we are looking at tissue affected by ARIA-E.

The best quality information about the relevant pathophysiological processes would be from biopsies or post-mortem samples from the time that ARIA occurred, but as far as we are aware no such samples exist. This is a substantial blind spot in the field of Alzheimer's research. Understanding the mechanisms behind ARIA takes on a renewed level of importance given the recent approval by the Federal and Drug Administration (FDA) of Aduhelm (aducanumab), an anti-A $\beta$  antibody, for the treatment of AD, with similar agents undoubtedly to follow. Aducanumab causes ARIA in clinical trials [60], and wider use may lead to more cases of ARIA. Especially given the controversy of whether aducanumab produces clinically meaningful improvement [61-63], we need a better understanding of ARIA to accurately appraise the balance of risks and benefits. Obtaining neuropathological correlates of ARIA should be a priority in the field.

### *Conclusions*

ARIA occurring in the context of A $\beta$  immunotherapy in AD is hypothesised to result from dynamic changes in the localisation of A $\beta$  with a shift of A $\beta$  from plaques to blood vessel walls. This increased CAA severity is likely associated with inflammation and is analogous to the spontaneous disease of CAA-related inflammation. ARIA-E may be due to failure to control water flux at the blood-brain barrier. In support of this hypothesis, we found that A $\beta$  immunotherapy is associated with increased in severity of capillary CAA, more so in carriers of APOE4 who are also at greater risk of ARIA. Therefore, exacerbation of capCAA could potentially counteract possible therapeutic benefit of lower plaque burden after immunisation, particularly in APOE4 carriers. Furthermore, capillary CAA is inversely related to AQP4 levels after immunisation, although we found no evidence of an overall change in AQP4 load or displacement of AQP4 from astrocyte endfeet. Limitations to our understanding of ARIA include the few cases from which tissue is available to study, lack of biopsies and difficulty in imaging of CAA and inflammation *in vivo*. The field must prioritise obtaining neuropathological correlates of ARIA to explore its mechanisms further.

### **Acknowledgments**

We would like to thank Dr Laura Palmer at the South West Brain Dementia Brain Bank (SWDBB) which is supported by BRACE (Bristol Research into Alzheimer's and Care of the Elderly) and provided the AD cases. We thank Elan Pharmaceuticals for access to phase I

AN1792 treatment study data and are grateful to all patients and carers who took part in the study. Our thanks also include the staff from Cardiff, Swindon, Oxford, Bath and Bristol Centres involved in the AN1792 study. We acknowledge the Histochemistry Research Unit and Biomedical Imaging Unit of the Faculty of Medicine, University of Southampton that facilitated tissue processing, staining and analysis.

#### *Funding*

The study was funded by the Alzheimer's Research UK (ART/PG2006/4, ART-EXT2010-1, ARUK-EG2015A-4) and the Medical Research Council UK (G501033). KS was supported by the SENSHIN Medical Research Foundation, KANAE foundation, and by the British Council Japan Association Scholarship.

#### **Ethical approval**

The study was covered for the iAD cases by the ethical approval from Southampton and South West Hampshire Local Research Ethics Committees (Reference No: LRC 075/03/w) and for the AD cases from the South West Dementia Brain bank by the NRES Committee South West Central Bristol, REC reference: 08/H0106/28 + 5. All donors have given informed consent for autopsy and use of their brain tissue for research purposes.

#### **Authors' contributions**

CHH and KS immunolabelled, performed quantification and collected data. DAJ provided technical assistance. CHH and DB performed statistical analyses. CH advised on the clinical relevance of the findings. CHH and DB wrote the manuscript. DB and JARN conceived and designed the study. All authors read and approved the final manuscript.

#### **Disclosure**

JARN has been a consultant/advisor relating to Alzheimer immunisation programmes for Elan Pharmaceuticals, GlaxoSmithKline, Novartis, Roche, Janssen, Pfizer, Biogen. DB has been consultant/advisor to Biogen. The other authors declare that they have no conflict of interests.

#### **Availability of data and material**

The dataset generated and/or analysed during the current study are available from the corresponding author on reasonable request.

#### **References**

- 1 Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med* 2016; 8: 595-608

- 2 Karran E, Hardy J. Anti-amyloid therapy for Alzheimer's disease--are we on the right road? *N Engl J Med* 2014; 370: 377-8
- 3 Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. *Neurology* 2005; 64: 94-101.
- 4 Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *Lancet* 2008; 372: 216-23
- 5 Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat Med* 2003; 9: 448-52
- 6 Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Abeta Species Removal After Abeta42 Immunization. *J Neuropathol Exp Neurol* 2006; 65: 1040-8
- 7 Nicoll JAR, Buckland GR, Harrison CH, Page A, Harris S, Love S, Neal JW, Holmes C, Boche D. Persistent neuropathological effects 14 years following amyloid- $\beta$  immunisation in Alzheimer's disease. *Brain* 2019; 142: 2113-26
- 8 Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. *Brain* 2008; 131: 3299-310
- 9 Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S, Nicoll JA. Abeta immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. *Acta Neuropathol* 2014:
- 10 Lee EB, Leng LZ, Lee VM, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. *FEBS Lett* 2005; 579: 2564-8
- 11 Zotova E, Holmes C, Johnston D, Neal JW, Nicoll JA, Boche D. Microglial alterations in human Alzheimer's disease following Abeta42 immunization. *Neuropathol Appl Neurobiol* 2011; 37: 513-24
- 12 Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. *Neuropathol Appl Neurobiol* 2003; 29: 106-17
- 13 Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, Weller RO. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. *Neuropathol Appl Neurobiol* 2008; 34: 131-44
- 14 Morris AW, Sharp MM, Albargothy NJ, Fernandes R, Hawkes CA, Verma A, Weller RO, Carare RO. Vascular basement membranes as pathways for the passage of fluid into and out of the brain. *Acta Neuropathol* 2016; 131: 725-36
- 15 Boche D, Denham N, Holmes C, Nicoll JA. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. *Acta Neuropathol* 2010; 120: 369-84
- 16 Sperling RA, Jack CR, Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-

modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. *Alzheimers Dement* 2011; 7: 367-85

17 Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. *Neurology* 2009; 73: 2061-70

18 Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurol* 2010; 9: 363-72

19 Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, Sims J, Sperling RA, Vellas B. The Future of Anti-Amyloid Trials. *J Prev Alzheimers Dis* 2020; 7: 146-51

20 Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. *Lancet Neurol* 2012; 11: 241-9

21 Greenberg SM, Parisi JE, Keegan BM. A 63-year-old man with headaches and behavioral deterioration. *Neurology* 2007; 68: 782-7

22 Boncoraglio GB, Piazza F, Savoirdo M, Farina L, DiFrancesco JC, Prioni S, Tagliavini F, Parati EA, Giaccone G. Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Abeta autoantibodies. *J Alzheimers Dis* 2015; 45: 363-7

23 Lowe J, Mirra SS, Hyman BT, Dickson DW. Ageing and dementia. In Greenfield's Neuropathology (8th ed) Eds. S Love, DN Louis, DW Ellison. London: Edward Arnold Ltd. 2008: 1031-152

24 Ellison D, Love S, Chimelli L, Harding BN, Lowe JS, Vinters HV, Brandner S, Yong WH. Vascular disease and infarcts. In Neuropathology Eds. D Ellison, S Love. Italy: Elsevier Mosby. 2013: 183-231

25 Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del Tredici K, Braak H. Two types of sporadic cerebral amyloid angiopathy. *J Neuropathol Exp Neurol* 2002; 61: 282-93

26 Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. *Acta Neuropathol* 2010; 120: 169-83

27 Richard E, Carrano A, Hoozemans JJ, van Horsen J, van Haastert ES, Eurelings LS, de Vries HE, Thal DR, Eikelenboom P, van Gool WA, Rozemuller AJ. Characteristics of dyschoric capillary cerebral amyloid angiopathy. *J Neuropathol Exp Neurol* 2010; 69: 1158-67

28 Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbrugg S, Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. *Neurobiol Aging* 2009; 30: 1936-48

29 Oshima K, Akiyama H, Tsuchiya K, Kondo H, Haga C, Shimomura Y, Iseki E, Uchikado H, Kato M, Niizato K, Arai H. Relative paucity of tau accumulation in the small areas with abundant Abeta42-positive capillary amyloid angiopathy within a given cortical region in the brain of patients with Alzheimer pathology. *Acta Neuropathol* 2006; 111: 510-8

- 30 Weller R, Boche D, Nicoll J. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. *Acta Neuropathologica* 2009; 118: 87-102
- 31 Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG. Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities. *Alzheimers Dement* 2013; 9: S105-15
- 32 Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. *Proc Natl Acad Sci U S A* 1994; 91: 13052-6
- 33 Solenov E, Watanabe H, Manley GT, Verkman AS. Sevenfold-reduced osmotic water permeability in primary astrocyte cultures from AQP-4-deficient mice, measured by a fluorescence quenching method. *Am J Physiol Cell Physiol* 2004; 286: C426-32
- 34 Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. *Nat Rev Neurosci* 2013; 14: 265-77
- 35 Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, Fujiyoshi Y, Engel A, Nielsen S. Aquaporin water channels--from atomic structure to clinical medicine. *J Physiol* 2002; 542: 3-16
- 36 Mishra A, Reynolds JP, Chen Y, Gourine AV, Rusakov DA, Attwell D. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles. *Nat Neurosci* 2016; 19: 1619-27
- 37 Owasil R, O'Neill R, Keable A, Nimmo J, MacGregor Sharp M, Kelly L, Saito S, Simpson JE, Weller RO, Smith C, Attems J, Wharton SB, Yuen HM, Carare RO. The Pattern of AQP4 Expression in the Ageing Human Brain and in Cerebral Amyloid Angiopathy. *Int J Mol Sci* 2020; 21:
- 38 Haj-Yasein NN, Vindedal GF, Eilert-Olsen M, Gundersen GA, Skare O, Laake P, Klungland A, Thoren AE, Burkhardt JM, Ottersen OP, Nagelhus EA. Glial-conditional deletion of aquaporin-4 (Aqp4) reduces blood-brain water uptake and confers barrier function on perivascular astrocyte endfeet. *Proc Natl Acad Sci U S A* 2011; 108: 17815-20
- 39 Vindedal GF, Thoren AE, Jensen V, Klungland A, Zhang Y, Holtzman MJ, Ottersen OP, Nagelhus EA. Removal of aquaporin-4 from glial and ependymal membranes causes brain water accumulation. *Mol Cell Neurosci* 2016; 77: 47-52
- 40 Wilcock DM, Vitek MP, Colton CA. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease. *Neuroscience* 2009; 159: 1055-69
- 41 Yang J, Lunde LK, Nuntagij P, Oguchi T, Camassa LM, Nilsson LN, Lannfelt L, Xu Y, Amiry-Moghaddam M, Ottersen OP, Torp R. Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease. *J Alzheimers Dis* 2011; 27: 711-22
- 42 Xu Z, Xiao N, Chen Y, Huang H, Marshall C, Gao J, Cai Z, Wu T, Hu G, Xiao M. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Abeta accumulation and memory deficits. *Mol Neurodegener* 2015; 10: 58
- 43 Mofakhar P, Lynch MD, Pomakian JL, Vinters HV. Aquaporin expression in the brains of patients with or without cerebral amyloid angiopathy. *J Neuropathol Exp Neurol* 2010; 69: 1201-9
- 44 Hoshi A, Yamamoto T, Shimizu K, Ugawa Y, Nishizawa M, Takahashi H, Kakita A. Characteristics of aquaporin expression surrounding senile plaques and cerebral amyloid angiopathy in Alzheimer disease. *J Neuropathol Exp Neurol* 2012; 71: 750-9



- 45 Zeppenfeld DM, Simon M, Haswell JD, D'Abreo D, Murchison C, Quinn JF, Grafe MR, Woltjer RL, Kaye J, Iliff JJ. Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. *JAMA Neurol* 2017; 74: 91-9
- 46 Yang J, Zhang R, Shi C, Mao C, Yang Z, Suo Z, Torp R, Xu Y. AQP4 Association with Amyloid Deposition and Astrocyte Pathology in the Tg-ArcSwe Mouse Model of Alzheimer's Disease. *J Alzheimers Dis* 2017; 57: 157-69
- 47 Boche D, Nicoll JA. The role of the immune system in clearance of Abeta from the brain. *Brain Pathol* 2008; 18: 267-78
- 48 Hasegawa H, Ma T, Skach W, Matthay MA, Verkman AS. Molecular cloning of a mercurial-insensitive water channel expressed in selected water-transporting tissues. *J Biol Chem* 1994; 269: 5497-500
- 49 Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskva V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* 2009; 41: 1088-93
- 50 Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* 2009; 41: 1094-9
- 51 Lane-Donovan C, Herz J. ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease. *Trends Endocrinol Metab* 2017; 28: 273-84
- 52 Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol* 2013; 9: 106-18
- 53 Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. *Ann Neurol* 2004; 55: 250-6
- 54 Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, Ellison D, Hilton DA, Williams TL, MacKenzie JM, Xuereb JH, Love S. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. *Brain* 2005; 128: 500-15.
- 55 Hermann DM, Keyvani K, van de Nes J, Weimar C, Wiltfang J, Nitsch RM, Szodorai A. Brain-reactive beta-amyloid antibodies in primary CNS angiitis with cerebral amyloid angiopathy. *Neurology* 2011; 77: 503-5
- 56 Piazza F, Greenberg SM, Savoirdo M, Gardinetti M, Chiapparini L, Raicher I, Nitrini R, Sakaguchi H, Brioschi M, Billo G, Colombo A, Lanzani F, Piscosquito G, Carriero MR,



- Giaccone G, Tagliavini F, Ferrarese C, DiFrancesco JC. Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. *Ann Neurol* 2013; 73: 449-58
- 57 Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, Boulouis G, Piazza F, DiFrancesco JC, Frosch MP, Pontes-Neto OV, Shoamanesh A, Reijmer Y, Vashkevich A, Ayres AM, Schwab KM, Viswanathan A, Greenberg SM. Validation of Clinoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. *JAMA Neurol* 2016; 73: 197-202
- 58 Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. *Brain Pathol* 2004; 14: 11-20.
- 59 Carlson C, Siemers E, Hake A, Case M, Hayduk R, Suhy J, Oh J, Barakos J. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease. *Alzheimers Dement (Amst)* 2016; 2: 75-85
- 60 VandeVrede L, Gibbs DM, Koestler M, La Joie R, Ljubenkov PA, Provost K, Soleimani-Meigooni D, Strom A, Tsoy E, Rabinovici GD, Boxer AL. Symptomatic amyloid-related imaging abnormalities in an APOE  $\epsilon 4/\epsilon 4$  patient treated with aducanumab. *Alzheimers Dement (Amst)* 2020; 12: e12101
- 61 Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. *Alzheimer's & Dementia* 2021; 17: 696-701
- 62 Liu KY, Schneider LS, Howard R. The need to show minimum clinically important differences in Alzheimer's disease trials. *The Lancet Psychiatry*.
- 63 Schneider L. A resurrection of aducanumab for Alzheimer's disease. *The Lancet Neurology* 2020; 19: 111-2

## Legends

**Figure 1.** Illustrations of cerebral cortical capillaries unaffected (A) and affected (B and C) by accumulation of A $\beta$  within and in close association with their walls (i.e. capillary CAA). Prominent capillary CAA was detected as early as 4 months after first A $\beta$  immunisation dose in one case (case no. 2) during what appeared to be a dynamic phase of plaque removal (D). In addition, in some long term survivors, marked capillary CAA in the absence of plaques was present in some cortical regions up to 14 years after immunisation indicating it could also be a longstanding and/or late recurrent feature (E, case no. 20; F, case no. 21; G, case no. 22, A $\beta$ 42 immunohistochemistry). Quantification showed significantly more capCAA in the cerebral cortex of immunised AD cases compared with untreated AD cases (H). The case known to have had ARIA (case no. 1) is indicated in red. Amongst the immunised AD cases, there was a trend for more capCAA in *APOE*  $\epsilon$ 4 carriers than non- $\epsilon$ 4 carriers ( $p=0.056$ ) (I). No such trend was evident in *APOE*  $\epsilon$ 4 carriers in untreated AD cases (J). Scale bar (A-C) = 50 $\mu$ m; (D-G) = 100 $\mu$ m.

**Figure 2.** Aquaporin 4 (AQP4) expression in the cerebral cortex is present in both the cell body and processes of astrocytes (A). There is particularly prominent AQP4 staining around many (B) but not all (C) capillaries, representing AQP4 in astrocyte end feet. Quantification showed no significant difference between immunised AD cases (iAD) and control AD cases (cAD) in either the density of capillaries wrapped by AQP4-containing endfeet (D) or overall AQP4 load (E, % area stained). The case known to have had ARIA (case no. 1) is indicated in red. Scale bar = 50 $\mu$ m.

**Table 1:** Demographic information on the immunised and non-immunised AD groups.

Case no. (iAD)	Sex	Dementia duration (years)	APOE status	Mean antibody response (ELISA units)	Survival time from first AN1792 immunisation (months)
1**	F	6	3.4	1:119	20
2	M	11	3.3	<1:100	4
3	M	6	3.3	<1:100	41
4	F	10	3.3	1:4072	44
6	M	7	3.4	1:1707	57
7	M	6	3.4	1:4374	60
8	M	10	3.4	1:6470	64
9	M	11	4.4	1:491	63
10	F	11	3.3	1:137	86
11	M	12	3.4	1:142	94
16	F	15	3.4	1:142	111
17	F	13	4.4	<1:100	141
19	F	19	Unknown	1:221	162
20	M	17	Unknown	1:430	166
21	F	18	3.4	1:3045	173
22	M	18	4.4	1:1313	184
cAD (n=28)	15 F: 13 M	3-17	21 ε4+ 6 ε4- 1 unknown	n/a	n/a

\*\* Case with ARIA-E; iAD: immunised Alzheimer's case; cAD: non-immunised Alzheimer's case; F: Female; M: Male; n/a: not applicable

**Table 2:** Correlations between the number of A $\beta$ 42+ capillaries (capCAA), AQP4+ capillaries (endfeet), overall AQP4 and A $\beta$ 42 load and the available clinical information in (A) the immunised AD group and (B) in the non-immunised AD group.



<b>A (iAD)</b>	<b>AQP4 end-feet</b>	<b>AQP4%</b>	<b>A<math>\beta</math>42%</b>	<b>Antibody peak</b>	<b>Antibody mean</b>	<b>Survival time</b>	<b>Dementia duration</b>	<b>Age at death</b>
<b>CapCAA</b>	$r_s = -0.208$ $p = 0.156$	<i><math>r_s = -0.498^{***}</math></i> <i><math>p &lt; 0.001</math></i>	$r_s = -0.018$ $p = 0.906$	$r_s = 0.287$ $p = 0.281$	$r_s = 0.238$ $p = 0.374$	$r_s = 0.063$ $p = 0.815$	$r_s = 0.125$ $p = 0.645$	$r_s = 0.084$ $p = 0.758$
<b>AQP4 end-feet</b>		<i><math>r_s = 0.317^*</math></i> <i><math>p = 0.032</math></i>	$r_s = 0.232$ $p = 0.113$	$r_s = 0.066$ $p = 0.807$	$r_s = 0.229$ $p = 0.394$	$r_s = -0.116$ $p = 0.668$	$r_s = -0.313$ $p = 0.238$	$r_s = 0.018$ $p = 0.948$
<b>AQP4%</b>			$r_s = -0.060$ $p = 0.690$	$r_s = -0.177$ $p = 0.512$	$r_s = 0.074$ $p = 0.786$	$r_s = -0.124$ $p = 0.649$	$r_s = -0.330$ $p = 0.211$	$r_s = 0.177$ $p = 0.512$
<b>A<math>\beta</math>42%</b>				$r_s = 0.109$ $p = 0.687$	$r_s = 0.065$ $p = 0.811$	$r_s = 0.100$ $p = 0.713$	$r_s = 0.081$ $p = 0.764$	$r_s = -0.298$ $p = 0.262$

<b>B (cAD)</b>	<b>AQP4 end-feet</b>	<b>AQP4%</b>	<b>A<math>\beta</math>42%</b>	<b>Dementia duration</b>	<b>Age at death</b>
<b>CapCAA</b>	$r_s = -0.123$ $p = 0.275$	$r_s = 0.002$ $p = 0.989$	$r_s = -0.060$ $p = 0.588$	$r_s = 0.004$ $p = 0.987$	$r_s = -0.056$ $p = 0.777$
<b>AQP4 end-feet</b>		<i><math>r_s = 0.547^{***}</math></i> <i><math>p &lt; 0.001</math></i>	$r_s = 0.024$ $p = 0.835$	$r_s = -0.172$ $p = 0.444$	<i><math>r_s = -0.487^{**}</math></i> <i><math>p = 0.010</math></i>
<b>AQP4%</b>			$r_s = -0.154$ $p = 0.172$	$r_s = -0.163$ $p = 0.468$	$r_s = 0.091$ $p = 0.652$
<b>A<math>\beta</math>42%</b>				$r_s = -0.167$ $p = 0.459$	$r_s = 0.258$ $p = 0.185$


$r_s$  Spearman's rank correlation;  $r$  Pearson's rank correlation; \*\* $p \leq 0.01$ ; \*\*\* $p \leq 0.001$ ; significant  $p$  values are in italic.






medRxiv preprint doi: <https://doi.org/10.1101/2022.12.08.22283144>; this version posted December 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

H



I



J

